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Introduction
Mesenchymal stem cells (MSCs) are multipotent stem cells
that can differentiate into osteoblasts, adipocytes and chon-
drocytes.1 MSCs appear to be immunosuppressive in vitro and
inhibit T-cell responses2,3 as well as modulate B-lymphocyte
proliferation and differentiation.4
Several clinical trials have been designed in an attempt to
explore their therapeutic potential in acute graft-versus-host
disease (GVHD),5,6 while the information available on the effi-
cacy of MSCs in the chronic GVHD setting is far more limited7
(www.clinicaltrials.gov). We have previously shown that the
expansion of MSC using human serum is feasible,8 and their
immunomodulatory properties were preserved and compara-
ble with MSC expanded using FCS. In order to prevent viral or
prion contamination, we designed a phase I/II clinical trial in
order to evaluate the potential benefit of the infusion of MSC
expanded using human serum (HS) among patients diagnosed
with either refractory acute or chronic graft-versus-host dis-
ease. (Code: CSM/EICH2005; N EudraCT: 2005-003674-14,
PEI: 06-076, ClinicalTrials.gov identifier NCT00447460).
Design and Methods
Mesenchymal stem cell collection and expansion
MSCs were obtained from 30-50 mL of bone marrow from healthy
donors of patients who had previously failed treatment once
informed consent for donation had been obtained. The method and
results of the procedure are shown in the Online Supplementary
Appendix. Among patients receiving related donor transplants, MSCs
were obtained from the same family donor, while for patients receiv-
ing an unrelated donor transplant, a related haploidentical donor or a
mismatched unrelated donor was used. One day before the harvest, a
plasmapheresis was planned in order to obtain 1,500-2,000 mL of HS
as previously reported, which was used for the in vitro MSC expan-
sion. Overall, 28 expansions were started although MSCs were not
infused in 11 cases. Reasons for not infusing the cells are summarized
in Table 1. 
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This trial evaluated the feasibility and efficacy of the infu-
sion of mesenchymal stem cells expanded using human
serum for the treatment of refractory acute or chronic graft-
versus-host disease. Twenty-eight expansions were started.
In 22, a minimum of more than 1x106 mesenchymal stem
cells/kg were obtained after a median of 26 days; this
threshold was not obtained in the remaining cases. Ten
patients received cells for the treatment of refractory or
relapsed acute graft-versus-host disease and 8 for chronic dis-
ease. One patient treated for acute graft-versus-host disease
obtained a complete response, 6 had a partial response and
3 did not respond. One of the chronic patients achieved
complete remision, 3 a partial response, and 4 did not
respond. The current study supports the use of this
approach in less heavily treated patients for both acute and
chronic graft-versus-host disease. The trial has been regis-
tered at ClinicalTrials.gov: identifier NCT00447460.
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ABSTRACT
MSC expansion procedure, cell characterization and obtaining
platelet lysate were performed according to standard procedures
and are shown in the Online Supplementary Appendix.  
Patients’ characteristics and MSC infusion
Overall, 18 patients diagnosed with either acute (n=10) or
chronic (n=8) GVHD refractory to prior treatment were includ-
ed in the study once written informed consent had been
obtained. Refractory GVHD was defined as progression or
absence of response to last treatment. Patients’ characteristics
are summarized in Table 2. Eleven patients had received
reduced intensity conditioning and 6 received myeloablative
conditioning. Fourteen patients had received hematopoietic
stem cells from an unrelated donor and 7 received them from an
HLA-mismatched donor. Eight patients had received GVHD
prophylaxis based on a calcineurin inhibitor plus methotrexate.
Inclusion criteria were: patients who had undergone an allo-
geneic stem cell transplant and developed GVHD refractory to
conventional treatment; adequate cardiac and pulmonary func-
tions; aged between 18 and 65 years; signed informed consent
from patient and donor. Exclusion criteria were: patients who
did not fulfill all of the inclusion criteria; progression of the
hematologic disease; active infection; women who were either
pregnant or at risk of pregnancy. The study was conducted
between February 2007 and December 2009.
Patients received 1-2x106 MSCs/kg intravenously in a single
dose. Eventually, when a partial response was obtained or in the
case of relapse after achieving complete remission, patients
could receive a second dose of MSCs at least two weeks after
the first infusion. Patients who were receiving 6-methyl-
prednisolone were kept on the same doses for at least seven
days after MSC infusion and a taper of 10% every five days was
planned later when there was a response. Other immunosup-
pressive drugs were managed according to the criteria of the
attending physician. Response to therapy was measured
according to previously reported criteria.9-11
Patients were taken off the study if fewer than 1x106
MSCs/kg were obtained after eight weeks of expansion. All
patients receiving at least one dose of MSCs were included in
the safety and efficacy analysis.
The treatment protocol was reviewed and approved by the
local authorities and ethical committee of all participanting cen-
ters.
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Table 1. MSC expansion.
ID Culture Total α Days of Type of Donor Infused Reason for not infusing
medium number Culture donor sex/age yes/no 
12 AS + PL 0.00 60 haploidentical F/48 No Not expanded 
5 AS 6 15 MRD F/61 No Death prior to expansion (*)
11 AS 15 34 haploidentical M/41 Yes
9 AS 38 25 haploidentical M/50 Yes
8 AS 40 13 haploidentical M/39 No Death prior to expansion (*)
6 AS 44 33 MRD F/65 No Death prior to expansion (*)
7 AS 53 33 MRD M/38 Yes
3 AS 56 43 haploidentical F/50 No Death prior to expansion (*)∞
23 AS + PL 69 24 MRD M/67 No Response to prior therapy
13 AS + PL 79 47 haploidentical M/56 Yes
1 AS 100 25 haploidentical F/44 Yes
14 AS + PL 100 33 haploidentical M/47 Yes
18 AS 119 35 haploidentical F/42 Yes
15 AS 132 23 haploidentical F/33 No Relapse
16 AS 150 27 haploidentical F/37 Yes
17 AS 178 27 haploidentical M/42 No Response to prior therapy
4 AS 180 30 haploidentical M/48 Yes
2 AS 186 36 haploidentical M/42 Yes
21 AS 245 30 MRD M/57 Yes
19 AS 268 23 haploidentical F/33 No Response to prior therapy
20 AS 335 24 haploidentical M/44 Yes
22 AS 350 26 haploidentical F/29 Yes
27 AS 350 20 haploidentical M/55 Yes
25 AS + PL 410 19 MRD M/40 Yes
28 AS + PL 450 29 MMURD M/33 No Response to prior therapy
24 AS + PL 520 26 MRD M/40 Yes
29 AS 792 17 MRD M/51 No Death prior to expansion (¥) ∞
26 AS + PL 884 26 MMURD F/53 Yes
AS: autologous serum; PL: platelet lysate; MRD: matched related donor; MMRUD: mismatched unrelated donor; F: female; M: male; (∞) MSCs were finally infused into a different
patient after informed consent had been obtained; (*) cause of death: GVHD progression; (¥) death due to infection; (α): total number ¥106.
Statistical analysis
Variables of the expansion procedure were analyzed from the
day of inclusion in the trial, i.e. the day when informed consent
was signed. Mean and median values and their corresponding
95% confidence intervals (CIs) and ranges were calculated for
each continuous variable. Student’s two-sample t test and
Pearson’s X2 test were used to compare continuous and qualita-
tive variables. In those comparisons where the number of cases
precluded the use of parametric tests, the Mann-Whitney test
and Fisher’s exact test were used. To analyze patient outcome
after infusion, events were calculated from the time of MSC
infusion. GVHD related mortality was defined as death due to
causes directly related to GVHD and those deaths attributed to
immunosuppression in patients requiring treatment for GVHD
were also considered as GVHD related mortalities. 
SPSS (version15.0; SPSS Inc, Chicago, IL, USA) was used for
most of the statistical analyses. Computations and testing of
cumulative incidences were performed with the cmprsk routine
in R (version 1.9.1). 
Differences were considered to be statistically significant
when two-tailed values of P < 0.05 were obtained.
Results
In vitro expansion of MSC
Overall, 28 expansions were started. In 2 of them, a
minimum of more than 1x106 MSCs/kg recipient body
weight were obtained after a median period of 26 days
(range 15-47 days), while the threshold was not obtained
after eight weeks of culture in the other 6 cases (Table 1).
In 5 out of 20 cases expanded using AS, the final thresh-
old was not reached, compared with one out of 8 cases
expanded using AS plus PL (P=0.4), although it should be
noted that PL was used only for those cases that had poor
expansion kinetics. No significant differences were
observed in the number of cells expanded with respect to
the sex or type of the donor.
Response and outcome
Table 3 shows the type of GVHD and line of treatment.
In the aGVHD setting, 5 patients received a single infu-
sion, while one patient each received two and three infu-
sions, and 3 patients received four infusions after having
obtained partial response to the first infusion. None of
those patients receiving more than one dose showed a
better quality response. One patient obtained complete
remission, 6 obtained partial response, and 3 patients did
not respond to MSC infusion. At final follow up, 2
patients were alive and 8 had died, 2 due to GVHD and
the others from causes different from other than GVHD. 
Table 3 shows data concerning refractory cGVHD. Four
patients received MSC as second-line and 4 patients as at
least third-line treatment. Four patients received a single
dose, 3 received two doses and one patient received three
doses of MSCs. The median dose of cells infused was
2x106/kg (range 0.3-3.7x106/kg). One patient achieved
complete remission, 3 showed a partial response and 3
did not respond. Notably, the patient who achieved com-
plete remission had severe thrombocytopenia that
resolved after MSC infusion and remained in complete
remission at the time of writing; however, 2 patients
obtaining a partial response subsequently relapsed. 
Discussion
Several clinical trials have already shown the feasibility
and efficacy of MSC infusion in patients diagnosed with
graft-versus-host disease.5-7 However, these trials used
MSCs expanded using fetal calf serum, which could
potentially favor the transmission of zoonoses. As we
have previously reported, human autologous serum repre-
sents a good alternative that allows for the expansion of
MSCs8 with biological characteristics similar to those
expanded in the presence of FCS. Thus, the current trial
provides confirmation in the clinical setting that expansion
of MSCs is feasible and may yield enough MSCs without
FCS, although the addition of platelet lysate to the autolo-
gous serum may increase the number of expanded cells in
those few cases with slow growth kinetics. This finding is
consistent with those of previous in vitro studies12-16 and a
clinical trial using this approach has already been report-
ed.17
No severe adverse event was observed either among
donors or among patients during or after the infusion of
MSCs. While several patients developed infectious
episodes after MSC administration, its occurrence in 4 of
the 10 patients with refractory acute GVHD is not an
unusually high incidence of infection in this setting. No
infectious episodes were reported among the 8 patients
treated for chronic GVHD so the MSCs did not appear to
increase the risk in this subset of patients. As regards effi-
cacy of the procedure, among patients diagnosed with
acute GVHD, one patient achieved and maintained com-
plete remission while only 3 patients did not respond.
Given the very high risk encountered by the patients in
our trial and the many prior lines of therapy, this response
rate is encouraging. However, this did not translate into
Table 2. Patients’ characteristics (N=18).
Patient a/c Sex/Conditioning Stem Type HLA GVHD
ID GVHD Age regime cell of donor prophylaxis
source
1 Acute F / 50 RIC PB Unrelated Matched CSA+MMF
2 Chronic M / 45 RIC BM Unrelated Mismatched CSA+MMF
4 Acute F / 21 RIC BM Unrelated Mismatched Tacro+MMF
7 Chronic F / 63 RIC PB Unrelated Mismatched Tacro + MMF
9 Acute M / 43 RIC BM Unrelated Mismatched Tacro + MTX 
+ ATG
11 Chronic M / 37 Myelo PB Unrelated Matched CSA + MTX
13 Chronic M / 31 Myelo PB Unrelated Matched Tacro + MTX
14 Chronic M / 21 Myelo BM Unrelated Mismatched CSA + MTX
16 Acute F / 43 RIC PB Unrelated Matched Tacro + MTX 
+ATG
18 Chronic F / 66 RIC PB Related Matched CSA + MTX
20 Chronic F / 32 RIC PB Related Matched CSA + MTX
21 Chronic F / 52 Myelo PB Related Matched Tacro + MMF
22 Acute M / 29 Myelo BM Unrelated Mismatched Tacro + MTX
24 Acute F / 31 Myelo PB Related Matched CSA + MTX
25 Acute M / 21 Myelo PB Unrelated Matched CSA + MTX
26 Acute M / 62 RIC PB Unrelated Matched Tacro + Rapa
27 Acute F / 24 RIC PB Unrelated Matched None
29 Acute M / 49 RIC PB Unrelated Mismatched Tacro + Rapa
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better survival, largely due to the severe performance sta-
tus of the patients. 
The poor prognosis of aGVHD refractory to steroids has
led to the search for new treatments but, even though
some groups have reported promising results in terms of
response, long-term overall survival remains in the range
of 5-15% in this subset of patients.18,19 Regarding cGVHD,
again a number of immunosuppressive agents have
demonstrated some activity, but most of these treatment
options have not been systematically investigated,
patients’ characteristics vary greatly between studies and
evidence is limited to phase II trials. Accordingly, a com-
Mesenchymal cells for graft vs. host disease treatment
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Table 3. Outcome of patients receiving MSCs for acute/chronic GVHD.
ID patient Organ Line of Number Number Number Number Response Duration Status Cause of
involvement treatment of cells of cells of cells of cells to MSC of the at last death
and global infused infused infused infused response follow up
grade x106/kg (1st ) x106/kg (2nd) x106/kg (3rd) x106/kg (4th)
1 Gut 4 1.6 No response - Dead GVHD
aGVHD IV
4 Skin, 3 1.6 1.6 PR 1 month Dead Relapse
aGVHD liver, gut
III
9 Gut 3 0.6 PR 3 days* Dead VOD
aGVHD IV
16 Gut 3 1.3 1.3 1.0 0.7 PR 1 month Dead Infectiona
aGVHD II
22 Skin, gut 4 1.1 1.1 1.1 1.0 PR 1 month Dead Infectionb
aGVHD III
24 Skin, gut 5 1.8 2.9 No response - Dead GVHD,
aGVHD IV relapse, 
multiorgan 
failure 
25 Gut 3 2.9 1.6 No response - Dead Infection,
aGVHD II multiorgan
failure
26 Skin, gut, 3 1.0 1.0 1.09 PR 2 weeks* Dead Sepsisd
aGVHD liver
II
27 Gut 3 0.9 0.9 0.9 0.9 PR 1 week Dead Sepsisd
aGVHD IV
29 Gut 3 1.1 1.20 CR 11 months ** Alive
aGVHD III/IV
2 Gut 3 1.20 1.04 PR 3 months Dead Liver biopsy
cGVHD severe
7 Skin, mouth, 6 0.6 NR - Dead GVHD
cGVHD gut, liver 
moderate/
severe
11 Ocular, skin 2 0.20 PR 1 year Alive
cGVHD mouth, gut  
Severe 
13 Mouth, 3 0.80 CR 1 year  ** Alive
cGVHD Thrombocytopenia
slight
14 Skin, gut 4 0.80 1.20 NR - Dead Toxicodermia
cGVHD Severe
18 Muscleskeletal, 3 1.05 1.05 PR 5 months Alive
cGVHD gut 
Severe
20 Muscleskeletal, 5 0.80 0.80 1.05 1.05 NR - Alive
cGVHD skin
Severe
21 Skin, gut 3 1.01 NR - Alive
cGVHD Severe  
*Until exitus; **Until last follow up; - No response; pneumonia two months after the last infusion of MSCs; pulmonary aspergillosis one month after the last dose of MSCs; (a)
aspergillus and adenoviral reactivation more than two months after the last infusion of MSCs; (b) sepsis due to E. coli.
parison of the results from the current study and other
approaches is not feasible.20
There is little published information about the use of
MSCs in the treatment of cGVHD  and no clinical trials
have been performed in this setting. The current study
includes the largest number of patients treated with MSC
for cGVHD. Remarkably, 3 patients showed a partial
response and one achieved complete remission. The latter
had mucosal involvement plus life-threatening thrombo-
cytopenia that resolved after a single dose of MSCs. We
have previously reported that patients with immune
thrombocytopenic purpura had functional abnormalities
in MSCs, which may influence the physiopathology of the
disease and could support the use of MSCs for the treat-
ment of these patients.21
In conclusion, the current study is the first clinical trial
to evaluate the feasibility and safety of MSCs expanded in
vitro using autologous serum for the treatment of acute and
chronic GVHD. In terms of MSC expansion, this proce-
dure yields enough cells in most cases, although the addi-
tion of platelet lysate may improve the growth kinetics.
No adverse events could be directly attributed to the
MSCs. The current study supports the development of
new trials focused on the use of this approach in less heav-
ily treated patients in order to confirm the efficacy of the
procedure and its impact on outcome. 
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